Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMGEN INC Director's Dealing 2012

Jul 31, 2012

29819_dirs_2012-07-31_3b1d3d01-5cf3-4c61-a14d-436cf1024250.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2012-07-27

Reporting Person: SHARER KEVIN W (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-07-27 Common Stock M 64000 $42.13 Acquired 164979 Direct
2012-07-27 Common Stock M 64000 $50.44 Acquired 228979 Direct
2012-07-27 Common Stock G 128000 Acquired 276494 Indirect
2012-07-27 Common Stock G 128000 Disposed 100979 Direct
2012-07-27 Common Stock S 57746 $82.24 Disposed 218748 Indirect
2012-07-27 Common Stock S 67816 $83.02 Disposed 150932 Indirect
2012-07-27 Common Stock S 2438 $83.77 Disposed 148494 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-07-27 Nqso (Right to Buy) $42.13 M 64000 Disposed 2015-04-29 Common Stock (64000) Direct
2012-07-27 Nqso (Right to Buy) $50.44 M 64000 Disposed 2016-04-28 Common Stock (64000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 4414.8286 Indirect

Footnotes

F1: These shares are being transferred to the reporting person's Living Trust.

F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 9,250 RSUs which fully vest on 4/28/2013; 22,750 RSUs which vest in two equal annual installments of 11,375 each commencing 4/26/2013; 60,000 RSUs which vest in two equal installments of 19,800 each on 4/25/2013 and 4/25/2014 and one installment of 20,400 on 4/25/2015; and 8,933 RSUs which vest in three installments of 2,947, 2,948 and 3,038 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.

F3: These shares include 46 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

F4: The price reported is an average price. The prices ranged from $81.68 to $82.68 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F5: The price reported is an average price. The prices ranged from $82.69 to $83.68 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F6: The price reported is an average price. The prices ranged from $83.685 to $83.88 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F7: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.